EVADE – Enabling AAV Vector-based Gene Therapies: Expanding Vector Genome Cargo Size and Enhancing Delivery Efficiency
LISBOA2030-FEDER-00713000-15992
July 01, 2025
— September 30, 2028
Projects
iBET has been involved in some of the most prestigious RD&I and technology transfer projects, with remarkable impact internationally at many scientific and technological domains.
Filters
URGENT – Finding the Right Route to the Lung: Unlocking pRecision Gene EditiNg Therapies for Cystic Fibrosis
FCT - Fundação para a Ciência e Tecnologia
January 01, 2026
— June 30, 2027
CARE – Machine Learning-driven CD19 CAR T cell Manufacturing for Improved Safety and Efficacy in the Treatment of Hematologic Cancers
FCT - Fundação para a Ciência e Tecnologia
January 01, 2026
— June 30, 2027
ITQB NOVA
3Dbig AAV – Exploring hiPSC-derived 3D Models to Tackle the Brain Innate Immune Response to Gene Therapy rAAV
FCT - Fundação para a Ciência e Tecnologia
July 01, 2025
— June 30, 2028
Sclavo Vaccines Association, Fondazione Biotecnopolo di Siena, Institut Pasteur, University of Antwerpen - Vaccinopolis, DZIF, ZEPAI, Leiden University Medical Center, Université Libre de Bruxelles, Norwegian Institute of Public Health, Università di Siena, iBET - Instituto de Biologia Experimental e Tecnológica
EVH – European Vaccines Hub for Pandemic Readiness
European Comission - EU4Health Programme
March 01, 2025
— February 28, 2029
CCDR – Recruitment of Highly Qualified HR
FSE and Fundo Social Europeu Mais
January 01, 2025
— November 30, 2027
CCDR – Therapeutic Virus Production Platform
FEDER - Fundo Europeu de Desenvolvimento Regional (European Fund for Regional Development)
September 01, 2024
— December 31, 2026
INTERFACE Mission Program
Portuguese Agency for Innovation (ANI - Agência Nacional da Inovação)
January 01, 2023
— June 30, 2026
Austrian Centre of Industrial Biotechnology, Karlsruche Institute of Technology, Leiden University Medical Center, Hamburg University, ICOSAGEN, FAU
MSCA Doctoral Network CAARE: Characterization and Recovery of Bionanoparticles for Vaccine Delivery and Gene Therapy
EC-HORIZON-MSCA-2023-DN-01
October 01, 2024
— September 30, 2028
ILevAA – Integrating Continuous Production and Purification for Leveraging Recombinant Adeno-Associated Viruses (rAAV) Manufacturing
Fundação para a Ciência e Tecnologia (FCT)
January 01, 2025
— June 30, 2026
PePOP – Recovery of bioactive peptides from olive pomace
Fundação para a Ciência e Tecnologia (FCT)
January 01, 2025
— June 30, 2026
eiMACpro – Engineering hiPSC-derived macrophages (eiMAC) with tunable pro-inflammatory phenotype
Fundação para a Ciência e Tecnologia (FCT)
February 03, 2025
— August 02, 2026
14 Partners Across 7 European Countries
MSCA Doctoral Network ORGESTRA: Advancing Organoid Technologies Through Joint Doctoral Training
EC HORIZON–MSCA-2023-DN-JD
March 01, 2024
— December 31, 2027
OneChain Immunotherapeutics, Josep Carreras Leukemia Research Institute, Severo Ochoa Center for Molecular Biology
CARxALL – A new therapeutic opportunity for t-cell acute lymphoblastic leukemia patients
European Innovation Council (EIC) - Transition Program
April 01, 2023
— March 31, 2026
Non-profit European Research Infrastructure Consortium
EATRIS – European Infrastructure for Translational Medicine
Haplo-iPS – Generation of Human Induced Pluripotent STEM Cells from Haplo-selected Cord Blood Samples
COST ACTION CA21151
October 11, 2022
— October 10, 2026
18 national partners
TEC4GREEN – Preparing the agro-industrial sector for future technological and environmental challenges
Recovery and Resilience Program
July 01, 2022
— June 30, 2026
Instituto Politécnico de Bragança, MORE- Laboratório Colaborativo Montanhas de Investigação, UTAD - Centro de Investigação e de Tecnologias Agro-Ambientais e Biológicas
Mush4Chol – Development of an efficient hypocholesterolemic formulation from mushroom bioresidues through a sustainable integrated strategy
FCT - Fundação para a Ciência e Tecnologia
March 01, 2023
— February 28, 2027
ITQB NOVA, FCT NOVA
LEDeffect – Understanding the mechanisms of inactivation of ultraviolet light emitting diodes to develop effective water disinfection systems
FCT - Fundação para a Ciência e a Tecnologia
March 01, 2022
— January 31, 2026
34 International Partners
ARDAT – Accelerating Research & Development for Advanced Therapies
Innovative Medicines Initiative - European Commission
November 01, 2020
— July 31, 2026
EXCELERATE – Advancing the manufacturing of EXtracellular vesicles derived from human pluripotent stem CELls for cardiac rEgeneRATive medicine
FCT - Fundação para a Ciência e Tecnologia
January 01, 2023
— December 31, 2025
Concluded Projects (Previous to 2020)
- CARDIOCONTRACT: Automated Cardiomyocyte Contractility Assay Instrument.
2018-2020, EUROSTARS-2 – 12529/19/Q - DiViNe – Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies: novel affinity ligands and biometric membranes.
2015-2019, H2020-LEIT-BIO-1-635770. Funded by the EU - INNOVATE – Investigating the Novel Valuable bio-therapeutics and expression systems.
2014-2017, ERA-IB-2/0007/2013, Funded by the EU - EDUFLUVAC – Combinatorial immunization strategy to educate the immune system towards cross recognition and coverage against antigenic drift in seasonal influenza virus exposure.
2013-2017, FP7-HEALTH-2013-INNOVATION. Funded by the EU. - EPIGENESIS – One Health approach to integrate Guadeloupe research on vector-borne and emerging diseases in the ERA.
2013-2016, FP7-REGPOT-2012-2013-1, funded by the EU. - BRAINVECTORS— From Brain Gene Transfer Towards Gene Therapy: Pharmacological Assessment of AAV, CAV and LVV.
2012-2016, FP7-PEOPLE-2011-IAPP. Funded by the EU. - SpeCCC – Specialised Cell Carrier Components.
2012-2015, FP7‐SME‐2012‐315717. Funded by the EU - NanoGene – Stem cell generation and manipulation by nanoparticle mediated gene transfer for the safe clinical application of gene-modified cells.
2011-2014, ENMED/0001/2010, funded by EuroNanoMed ERA-Net. - PREDECT – New Models for Preclinical Evaluation of Drug Efficacy in common solid tumours.
2011-2016, GRANT AGREEMENT No. 115188, funded by IMI (Innovative Medicines Initiative) Joint Undertaking, funded by EU. - ComplexINC – New Technologies and Production Tools for Complex Protein Biologics.
2011-2015, FP7 / SME-targeted research for developing tools and technologies for high-throughput research, funded by EU. - CAREMI – Cardio Repair European Multidisciplinary Initiative.
2010-2015, HEALTH-F5-2010-242038, funded by EU - HYPERLAB – high yield and performance stem cell lab.
2009-2012, funded by EU (223011) - BrainCAV: Gene Transfer for Brain Therapy.
2008-2012, funded by EU (FP7-222992) - CLINIGENE-NoE: European Network for the Advancement of Clinical Gene Transfer and Therapy.
2006-2011, LSHB-CT-2006-018933, funded by the EU - VITROCELLOMICS – Reducing Animal Experimentation in Preclinical Predictive Drug Testing by Human Hepatic in vitro Models Derived from Embryonic Stem Cells.
2006-2009, funded by EU (LSHB-CT-2006-018940) - BACULOGENES – Baculovirus Vectors for Gene Therapy.
2006-2009, FP6 – 2007, funded by the EU - MARKVAC – Development of marker vaccines, companion diagnostic tests and improvement of epidemiological knowledge to facilitate control of rinderpest and peste des petits ruminants viruses.
2005-2007, RP/PPR MARKVAC, funded by the EU - EPIGENEVAC – Epidemiology and new generation vaccines for Ehrlichia and Anaplasma infections of ruminants.
2005-2009, FP6-003713-INCO-DEV-1, funded by the EU - CELLPROM – Cell Programming by Nanoscaled Devices.
2004-2009, NMP4-CT-2004-500039, funded by the EU - INSERTAGENE – Integrated Strategies for efficient therapeutic retrovirus based on modular cell lines.
2003-2005, QLK3-CT-2002-01949, funded by the EU - ROTASAFE – Novel strategies for a safe rotavirus vaccine.
2003-2005, QLRT-2001-01249, funded by the EU - COWDRIA – Mass production of Cowdria ruminantium to produce a cost effective veterinary vaccine against heartwater.
2001-2004, 8-ACP-TPS-040, funded by the EU - ORALVAC – Development of Oral Vaccines, Role of Wildlife in The Maintenance of these Diseases.
2001-2004, ICA4-CT-2000-30027, funded by the EU
- ERAdicatPH: Understanding primary hyperoxaluria type 1 towards the development of innovative therapeutic strategies.
2016-2019, E-Rare3/0002/2015, funded by FCT, Portugal - Therapeutic Targets for Triple Negative Breast Cancer: Development of mono and bispecific antibodies against Notch1 ligands.
2016-2019, PTDC/BBB-BMD/4497/2014, funded by FCT, Portugal - NETDIAMOND: New targets in diastolic heart failure: from comorbidities to personalized medicine.
2016-2019, POCI-01-0145-FEDER-016385 - CardioRegen: Integrative studies from the embryo to Scalable Multipronged Generation of hESC-derived Myocardial progenitors for heart repair.
2015-2019, HMSP-ICT/0039/2013, HMS program, funded by FCT, Portugal - Engineering biosensors for human cell type and state diagnosis using synthetic digital computation.
2018-2019, MIT-EXPL/BIO/0097/2017 - Establishment of a flexible insect cell platform for fast production of pseudo-typed VLPs for drug and vaccine development.
2014-2015, EXPL/BBB-BIO/1541/2013, funded by FCT, Portugal - Molecular approaches to develop an insect cell production system for Hepatitis C vaccine candidate.
2014-2015, EXPL/BBB-BIO/1129/2013, funded by FCT, Portugal - Development of a scalable strategy for stem cells purification.
2013-2014, EXPL/BBB-EBI/1003/2012, funded by FCT, Portugal. - Systems biotechnology for improved production of biopharmaceuticals in animal cells.
2013-2015, PTDC/BBB-BSS/0518/2012, funded by FCT, Portugal. - Combining siRNA and AAV therapy approaches to target human basal-like breast cancer: from vector development to anti-tumor efficacy evaluation.
2013-2015, PTDC/BBB-BIO/1240/2012, funded by FCT, Portugal. - Integrative approaches to depict human cardiac stem cell receptome and its role in the cardiac regenerative process.
2013-2015, PTDC/BBB-BIO/1414/2012, funded by FCT, Portugal. - A novel generation of packaging cell lines for the manufacture of lentivirus based biopharmaceuticals.
2012-2015, PTDC/EBB-BIO/118615/2010, funded by FCT, Portugal. - Development of improved suspension MDCK cell lines for the production of viral based bioproducts: manufacturing Influenza and Adenovirus.
2012-2015, PTDC/EBB-EBI/118621/2010, funded by FCT, Portugal. - Human central nervous system in vitro models for preclinical research: new tools for studying viral vector-mediated gene.
2012-2015, PTDC/EBB-BIO/119243/2010, funded by FCT, Portugal. - Probing adenovirus-host cell interactions: a systems biotechnology approach to improve production of gene delivery vectors.
2012-2015, PTDC/EBB-BIO/119501/2010, funded by FCT, Portugal. - Development of function blocking antibodies using Phage Display Technology: Inhibiton of the Notch1 signaling pathway by function blocking anti-jagged 1 antibody.
2012-2016, PTDC/SAU-ONC/121670/2010, funded by FCT, Portugal - MSVida: The architecture of life – Probing the quaternary structure of virus capsids by native mass spectrometry.
2012-2016, RECI/BBB-BEP/0104/2012, funded by FCT, Portugal - 3D in vitro models for reducing animal experimentation in pharmaceutical development: integrative approaches for prediction of hepatic drug metabolism and neurotoxicity.
2011-2014, PTDC/EBB-BIO/112786/2009, funded by FCT, Portugal. - Preconditioning triggered by Carbon monoxide: new strategies to prevent brain damage due to hypoxia-ischemia and reperfusion.
2010-2012, PTDC/SAU-NEU/098747/2008, funded by FCT, Portugal. - 2D fluorometry: a powerful tool to improve mammalian cell process development.
2010-2012, PTDC/EBB-EBI/102750/2008, funded by FCT, Portugal. - Novel Cell Factories for the production of secreted complex bioproducts: a syntetic biology approach for improved product Stoichiometries.
2010-2012, PTDC/EBB-EBI/102266/2008, funded by FCT, Portugal. - BACULOME-Engineering cellular energetics for improvement of bioprocesses: metabolic modeling for enhanced vaccines production.
2010-2012, PTDC/EBB-EBI/103359/2008, funded by FCT, Portugal. - Retroviral like particles: improving potential as candidate vaccines for Hepatitis C.
2010-2012, PTDC/EBB-BIO/102649/2008, funded by FCT, Portugal. - Using functional genomics to improve mammalian cells for virus based biopharmaceuticals manufacture.
2010-2012, PTDC/EBB-BIO/100491/2008, funded by FCT, Portugal. - Integrated strategies for expansion, neuronal differentiation and cryopreservation of human embryonic stem cells.
2009-2012, funded by FCT (PTDC/BIO/72755/2006) - Fundamentals of downstream processing of enveloped viruses: towards an integration of purification processes.
2007-2010, funded by FCT (PTDC/EQU-EQU/71645/2006) - Manufacturing canine adenovirus vectors for gene therapy: development of MDCK CAV-2E1- transcomplementing cell lines.
2007-2010, funded by FCT (PTDC/BIO/69452/2006) - Development of flexible cell lines for the Production of Retrovirus and Lentivirus for Gene Therapy.
2007-2010, funded by FCT (PTDC/BIO/69451/2006) - Novel stroke model for neuroprotective research: bioreaction of primary brain cell aggregates.
2007-2010, funded by FCT (PTDC/BIO/69407/2006) - Carbon monoxide as a neuroprotective agent against hypoxia-ischemia and reperfusion.
2007-2010, funded by FCT, Portugal (PTDC/SAU-NEU/64327/2006) - Advanced Control of BHK Cultivation Processes Based on Intracellular Metabolic Fluxes.
2005-2007, funded by FCT, Portugal (POCI/BIO/57927/2004) - THERAVECT – Production, Purification and Storage of Retroviral Vectors Produced by Modular Master Producer Cells.
2005-2007, funded by FCT, Portugal (010.6/A003/2005) - CELL CRYOTHERA – Cell Cryopreservation for Therapy and Regenerative Medicine.
2005-2007, funded by FCT, Portugal (010.6/A006/2005) - Genetics, Stoicheometry and Kinetics of Multiple Protein Assembly: the case for a Rotavirus Like Particle.
2005-2007, funded by FCT (POCTI/BIO/55975/2004) - Integrated strategy for the production, purification and storage of adenovirus.
2004-2006, funded by FCT, Portugal (POCTI/BIO/46515/2002) - Metabolic Trafficking between neurons and astrocytes under stress conditions implicated in neurological disorders.
2003-2006, funded by FCT, Portugal (POCTI/BIO/39214/2001) - Stabilization of retroviruses for gene therapy clinical applications.
2001-2003, funded by FCT, Portugal (POCTI/BIO/35695/2000) - Cell cycle control for better biotechnological methods in therapeutic protein production.
2001-2003, funded by FCT, Portugal (POCTI/BIO/35687/2000)